MiNK Therapeutics, Inc. — Director's Dealing 2021

Oct 21, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2021-10-13

Reporting Person: van Dijk Marcus Antonius (Chief Technology Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.02	2028-11-08	Common Stock (83490)		Direct
Stock Option (Right to Buy)	$0.02	2028-11-19	Common Stock (20872)		Direct
Stock Option (Right to Buy)	$0.02	2022-12-31	Common Stock (20872)		Direct
Stock Option (Right to Buy)	$0.01	2030-01-30	Common Stock (55660)		Direct
Stock Option (Right to Buy)	$3.03	2031-02-11	Common Stock (55660)		Direct

Footnotes

F1: Represents an option to purchase shares of the common stock, which vests in four equal annual installments beginning on March 1, 2019.

F2: Represents an option to purchase shares of the common stock, which vests as to 30% of the underlying shares on November 19, 2021 and as to the remaining 70% of the underlying shares on November 19, 2022, in each case, generally subject to continued employment.

F3: Represents an option to purchase shares of the common stock, as determined by the achievement of certain milestones

F4: Represents an option to purchase shares of the common stock, which vests in four equal annual installments beginning on January 30, 2022.

F5: Represents an option to purchase shares of our common stock, which vests as to 33% of the underlying shares on February 11, 2022, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.